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Protein Kinase C m (PKCm) Associates
with the B Cell Antigen Receptor Complex
and Regulates Lymphocyte Signaling
Svetlana P. Sidorenko,* Che-Leung Law,* 1994). While Ser/Thr kinase activity has been found as-
sociated with the BCR (Leprince et al., 1992; Van NoeselStephen J. Klaus,† Karen A. Chandran,*
Minoru Takata,§ Tomohiro Kurosaki,‡ et al., 1990, 1991; Williams et al., 1994), the kinases
responsible for this activity have not been identified,and Edward A. Clark†*
*Department of Microbiology and structural and functional links between PTK/PTP
cascades and Ser/Thr kinases are not well established.†Department of Immunology
University of Washington PTKs trigger a cascade of secondary signals that
activate phospholipase C-g1/2 (PLCg1/2), GTPase-acti-Seattle, Washington 98195
‡Department of Molecular Genetics vating protein (GAP), phosphoinositide 3-kinase (PI
3-kinase), and mitogen-activated protein kinase (De-Institute for Hepatic Research
Kansai Medical University Franco, 1995; Gold et al., 1992; Pleiman et al., 1994b).
Activation of PLCg requires both its tyrosine phosphory-Moiriguchi 570
Japan lation and translocation to the membrane via the Src
homology 2 (SH2) domains of PLCg (Pawson, 1995).§Department of Medicine II
Okayama University Medical School Activated PLCg catalyzes the hydrolysis of phosphoino-
sitides and generation of thesecond messengers diacyl-Okayama 700
Japan glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3),
which initiate the release of intracellular Ca21 (Berridge,
1993). In B lymphocytes, PLCg activation is regulated
by Lyn, Syk, and Btk (Takata and Kurosaki, 1996; TakataSummary
et al., 1994). Syk is required for PLCg activation and
can both tyrosine phosphorylate PLCg1 in vitro and beWe have identified a Ser/Thr kinase associated with
bound by the carboxy SH2 domain of PLCg1, whichthe B cell receptor (BCR) complex as protein kinase
recognizes specific phosphotyrosine motifs (Law et al.,C m (PKCm). PKCm activity is up-regulated after cross-
1996a; Sillman and Monroe, 1995). Studies of the Syk-linking the BCR and CD19 on B cells, and PKCm co-
and PLCg2-deficient variants of a chicken B cell lineprecipitates with Syk and phospholipase C-g1/2
DT40 showed that Syk-mediated activation of PLCg2 is(PLCg1/2). In vitro phosphorylation of fusion proteins
also required for BCR-induced apoptosis (Takata et al.,showed that both Syk and PLCg1 are potential sub-
1995).strates of PKCm in vivo. Analysis of mutants of the
Previously, we have found that in human B lympho-chicken B cell line DT40 deficient in either Syk, Lyn,
cytes both Syk and PLCg1/2 coprecipitate with a 120Btk, or PLCg2 revealed that BCR-induced activation
kDa Ser/Thr phosphoprotein, pp120 (Sidorenko et al.,of PKCm, like activation of PLCg2, requires Syk and
1995). Here we report that pp120 is the Ser/Thr kinaseis partially regulated by Btk, but is Lyn independent.
PKCm, an atypical member of the protein kinase C (PKC)PKCm can down-regulate the ability of Syk to phos-
family (Johannes et al., 1994). PKCm associates with thephorylate PLCg1 in vitro. Thus, PKCm may function
BCR and, like PLCg1/2, is activated after BCR engage-in a negative feedback loop regulating BCR-initiated
ment via a Syk-dependent process. Our results alsosignaling cascades.
demonstrate that BCR-induced activation of PKCm, like
activation of PLCg2, requires Syk but is Lyn indepen-Introduction
dent. We also found that PKCm inhibits the ability of Syk
to phosphorylate PLCg1 in vitro, indicating that PKCmThe B cell antigen receptor (BCR) complex is composed
may function as a negative regulator of BCR-mediatedof the antigen-recognizing component, surface immu-
signaling.noglobulin (sIg), and the Iga–Igb heterodimer, responsi-
ble for cell transport and signal transduction (Neuberger
et al., 1993; Reth, 1994). Initiation of cellular responses Results
via the BCR is regulated by protein tyrosine kinases
(PTKs) and protein tyrosine phosphatases (PTPs) (De- The Syk- and PLCg-Associated Phosphoprotein,
pp120, Is PKCmFranco, 1995; Weiss and Littman, 1994). Members of
the Src (Lyn, Blk, Lck, and Fyn), Syk, Tec, and Csk PTK We previously found that the Syk- and PLCg-associated
phosphoprotein pp120 was not rasGAP, the p120 sub-families interact or are activated (or both) upon receptor
engagement (Bolen, 1995; Cambier et al., 1994). In par- strate for Src family kinases, p125Fak, thep110 catalytic
subunit of PI 3-kinase, or the Jak1 and Jak2 kinasesticular, Lyn and Syk PTKs are associated with the “rest-
ing” BCR and immediately become tyrosine phosphory- (Sidorenko et al., 1995). Thus, we hypothesized that
pp120 itself is a Ser/Thr kinase and that BCR ligationlated following receptor ligation (Pleiman et al., 1994a).
Cross-linking the BCR also leads to activation of Bru- enhances its autophosphorylation. A putative candidate
for a Ser/Thr kinase about 115–120 kDa in size waston’s tyrosine kinase (Btk), a member of the Tec family.
At least two PTPs, CD45 and SHP1, appear to be in- PKCm, a recently cloned, atypical member of the PKC
family (Johannes et al., 1994). A second possibility wasvolved in regulation of signal transduction via the BCR
(Hunter, 1995; Justement et al., 1994; Sun and Tonks, that the120 kDa protein associated with Sykwas p120cbl,
Immunity
354
Figure 1. The 120 kDa Phosphoprotein Asso-
ciated with Syk and PLCg1/2 Is the Ser/Thr
Kinase PKCm
(A) Ramos cells were stimulated via sIgM for
3 min, and Syk, PLCg1, p120cbl, PKCm, and
BCR were immunoprecipitated from NP-40
(lanes 1–5) or digitonin (lanes 6–8) lysates.
Normal rabbit IgG was used as a negative
control for rabbit antisera, and mouse MAb
MOPC serves as a negative control for mouse
anti–IgM MAb. Immunoprecipitated proteins
were labeled by in vitro kinase assays and
resolved by SDS–PAGE under reducing con-
ditions. Each immunoprecipitation was per-
formed from equal amount of cells (107).
(B) Sequential immunoprecipitation of pp120
with anti-PKCm antibodies. After primary im-
munoprecipitation as described in (A), bands
110–120 kDa in size were eluted from dried
gels and reprecipitated with either anti-PKCm
antiserum or normal rabbit IgG (Control).
To reduce overexposure, we loaded eluates
in the amount of 10% of the volume that
was used for specific immunoprecipitations.
pp120 from either Syk, PLCg1, PLCg2, or
BCR immunoprecipitates was specifically
reprecipitated with anti-PKCm antibodies;
however, p120cbl did not reprecipitate with
anti-PKCm sera (data not shown). One of four
representative experiments is shown.
(C) The presence of PKCm in PLCg1 immuno-
precipitates was revealed by Western blot-
ting. PKCm and PLCg1 were immunoprecipi-
tated from the Ramos cell line with specific
antisera, and Western blotting with anti-
PKCm(C) serum was performed using en-
hanced chemiluminescence. Normal rabbit
IgG served as a negative control. One of three
experiments is shown.
since the p120cbl proto-oncogene product was found to PLCg1/2-associated pp120, but were able to reprecipi-
tate p120cbl by itself after elution from the gel (data notform a complex in T cells with Fyn, the p85 subunit of
PI 3-kinase, and the adaptor protein Grb2 (Fukazawa shown). Western blotting also did not detect p120cbl in
Syk and PLCg1/2 immunoprecipitates from either rest-et al., 1995). To characterize pp120 further, either Syk,
PLCg1, PLCg2, p120cbl, or PKCm was immunoprecipi- ing or anti-IgM-activated B cells (data not shown).
Since PKCm was specifically coprecipitated with ei-tated with associated proteins from the B cell lines
Ramos and Daudi and were labeled by 32P in an in vitro ther Syk or PLCg1/2, which are important components
of the BCR signaling cascade, and a Ser/Thr kinasekinase assay (Figure 1A). The electrophoretic mobility
of the pp120 coprecipitated with Syk (Figure 1A, lane activity has been reported to associate with the BCR
complex (Leprince et al., 1992, 1993; Van Noesel et al.,2), and with PLCg1 (lane 3) or PLCg2 (data not shown),
and was similar to that of PKCm (lane 5); however, p120cbl 1991; Williams et al., 1994), we next asked whether
PKCm is also associated with the BCR. The BCR wasmigrated more slowly (lane 4). 32P-labeled proteins from
the bands of interest (110–120 kDa) were eluted from immunoprecipitated in nonionic detergent digitonin and
subjected to in vitro kinase assay (Figure 1A, lanes 6–8).dried gels and reprecipitated with either control, anti-
PKCm, or anti-p120cbl antibodies. Sequential immuno- Sequential immunoprecipitation of phosphorylated pro-
teins showed that PKCm was associated with the BCRprecipitation analysis confirmed that the 115–120 kDa
phosphoprotein in PKCm immunoprecipitates was in- both before and after anti-IgM stimulation (Figure 1B).
Stoichiometrically, the level of PKCm associated withdeed PKCm and showed that the pp120 coprecipitated
with Syk and PLCg1/2 was PKCm (Figure 1B). Using BCR is much lower than that associated with either
PLCg1/2 or Syk, because to achieve equivalent signals,three antibodies to PKCm that recognize distinct subdo-
mains of human PKCm, we specifically reprecipitated reprecipitation of PKCm from BCR complexes required
about 10 times more cells than from PLCg1 immunopre-pp120 associated with Syk and PLCg1/2 from both rest-
ing and anti-IgM-activated Daudi and Ramos cell lines. cipitates. Western blotting of proteins coprecipitated
with PLCg1 revealed the presence of PKCm (Figure 1C).Antibodies to p120cbl did not reprecipitate Syk- and
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Figure 2. Activation of PKCm by Cross-Linking BCR
(A) Kinetics of PKCm activation after BCR cross-linking. In vitro kinase assays with exogenous substrate MBP on immunoprecipitates with
anti-PKCm(N) and anti-PKCm(C) antisera, as revealed on a gradient gel. One of three experiments is shown.
(B) Phosphorimaging analysis of PKCm autophosphorylation and MBP transphosphorylation, using two different antisera as in (A).
(C) Expression of PKCm in the following human lymphoid cell lines: pre-B cell lines Reh and Nalm6; Burkitt’s lymphoma cell lines Ramos and
Daudi; B cell lymphoma cell line B104; B lymphoblastoid cell line CESS; myeloma cell line RPMI-8226; and a T cell line Jurkat. Western blotting
was performed with anti-PKCm. One of four experiments is shown.
(D) Activation of PKCm in T cells after TCR cross-linking. PKCm was immunoprecipitated from T cell line Jurkat 5 min after anti-CD3 activation,
and its activity was measured by autophosphorylation and MBP phosphorylation.
(E) Autophosphorylation of PKCm isolated under stringent conditions after BCR cross-linking on Ser/Thr residues in Ramos cell line (see
Experimental Procedures).
(F) PKCm was immunoprecipitated in 0.5% NP-40 with associated proteins from the Ramos cell line after BCR cross-linking. Shown is
phosphorylation of PKCm by coprecipitated PTK on tyrosine. Positions of standard amino acids are shown by broken lines. S, phosphoserine;
T, phosphothreonine; Y, phosphotyrosine.
However, PKCm was not detected by Western blotting detected as early as 20 s after BCR stimulation, peaked
at 1 min, was sustained for at least 20 min, and graduallyin Syk, PLCg2, and BCR immunoprecipitates (data not
shown), probably owing to much lower sensitivity of diminished over the next 40 min. Identical magnitude
Western blotting compared with in vitro kinase assays. and kinetics of PKCm activation were observed in the
These experiments show that the Ser/Thr kinase PKCm presence of EGTA, which prevents influx of extracellular
is associated with Syk, PLCg1/2, and the BCR. Ca21 (data not shown). Notably, using anti-PKCm(C) se-
rum, which immunoprecipitates more protein than the
anti-PKCm(N) serum, and with the fine resolution in gra-Involvement of PKCm in Signal
Transduction via the BCR dient gels, PKCm appeared as a doublet (Figure 2A). The
increased autophosphorylation of PKCm was accompa-Since PKCm associates with the BCR, we explored
whether the activity of PKCm was affected by sIgM nied by a shift of electrophoretic mobility from 115 to
120 kDa (Figure 2A).cross-linking. sIgM was cross-linked with F(ab9)2 frag-
ments of goat anti–human IgM antibodies, and PKCm The tissue distribution of PKCm is ubiquitous (Johan-
nes et al., 1994). It is expressed in B cells at all stageswas immunoprecipitated with antibodies raised against
either its N-terminal or C-terminal domains. Both the of maturation from the pre-B cell to plasma cell stages
and also inT cells (Figure2C). The mechanisms of signal-autophosphorylation of PKCm and phosphorylation of
an exogenous substrate, myelin basic protein (MBP), ing via the BCR and the T cell receptor (TCR) have many
similarities (Weiss and Littman, 1994), and Ser/Thr-were measured after in vitro kinase assays. BCR cross-
linking led to a rapid 2- to 4-fold activation of PKCm, phosphorylated pp120 was associated with Syk and
PLCg1 in a T cell line Jurkat (Sidorenko et al., 1995).detected with bothautophosphorylation and transphos-
phorylation of MBP (Figures 2A and 2B). Activation was Therefore, we tested whether PKCm is also activated
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Figure 3. Up-Regulation of PKCm Activity
after Cross-Linking of BCR and CD19
PKCm was immunoprecipitated from the
Ramos cell line, which was activated for 3
min with different stimuli. PKCm activity was
measured by MBP phosphorylation in in vitro
kinase assays (A) and evaluated by phos-
phorimaging analysis (B) as in Figure 2A. One
of three representativeexperiments is shown.
after TCR ligation. After TCR ligation, autophosphoryla- not appear to changeafter BCR ligation (Figure 4A, lanes
9 and 10). At the same time, anti-IgM activation markedlytion of PKCm and MBP phosphorylation were increased
about 2-fold and 8-fold, respectively (Figure 2D). Phos- increased tyrosine phosphorylation of Syk, PLCg1, and
PLCg2 (Figure4A). PKCm immunoprecipitates containedphoamino acid analysis revealed autophosphorylation
of PKCm and phosphorylation of MBP only on Ser/Thr a number of tyrosine-phosphorylated proteins, including
those migrating at 145 and 72 kDa (Figure 4B, lanes 7residues in both B (Figure 2E) and T cells (data not
shown). However, weak tyrosine phosphorylation of and 8). Western blotting of PKCm immunoprecipitates
with anti-PLCg1 serum confirmed that the 145 kDa pro-PKCm was detected after BCR (Figure 2F) or TCR cross-
linking (data not shown), when PKCm was immunopre- tein associated with PKCm was PLCg1 (Figure 4C). Al-
though the PLCg1 associated with PKCm displayedcipitated with associated proteins. This suggests that
PKCm might be an in vitro substrate for associated PTKs increased tyrosine phosphorylation after BCR cross-
linking (Figure 4B), the level of PLCg1 associated withthat are activated by BCR or TCR cross-linking.
PKCm in B cells was activated not only after BCR PKCm did not change (Figure 4C). The tyrosine-phos-
phorylated protein of 72 kDa that coprecipitated withcross-linking, but also after signaling via CD19. How-
ever, CD22 and CD40 receptor engagement alone or in PKCm migrates similarly to Syk (Figure 4B), but we did
not detect Syk after Western blotting of PKCm immuno-combinations with sIgM or CD19 ligation did not alter
PKCm activity (Figures 3A and 3B). These results sug- precipitates with anti-Syk serum (data not shown). Con-
sistent with these results, the reciprocal experiment ofgest that PKCm is activated by signals that induce activ-
ity and tyrosine phosphorylation of PLCg1/2, eliciting Western blotting with anti-PKCm antiserum revealed
PKCm in PLCg1 immunoprecipitates, but not in Syk im-release of intracellular Ca21 (Carter et al., 1991b; Rijkers
et al., 1990; Weiss and Littman, 1994). We therefore munoprecipitates (Figure 1C).
tested whether PKCm can be activated by ionomycin,
which could release Ca21 from intracellular stores with- PKCm Phosphorylates Both Syk and PLCg1
on Serine Residuesout affecting PLCg. Incubation of cells with 500 ng/ml
ionomycin did not induce activity of PKCm. Treatment To determine potential intracellular targets for PKCm,
we tested the ability of PKCm to phosphorylate differentof cells with 50 ng/ml phorbol myristate acetate, which
competes with DAG for binding to the C1 region of PKC, substrates using in vitro kinase assays. Since PKCm was
coprecipitated with theBCR, Syk and PLCg1/2, themostactivated PKCm about 6-fold, in agreement with results
obtained in nonlymphoid tissues (Johannes et al., 1994, likely potential PKCm targets, were components of the
BCR, coreceptor molecules associated with the BCR, or1995). Taken together, our data clearly show that PKCm
is activated after ligation of the BCR and CD19 in B cells components of the BCR signal-transducing machinery.
Members of the PKC family phosphorylate substratesand the TCR in T cells; they also suggest that PKCm is
a Ca21-independent enzyme. at Ser/Thr residues lying near the basic residues arginine
and lysine, and PKCm apparently prefers substrates with
basic residues upstream of the phosphorylatable serineBCR Cross-Linking Increases the Tyrosine
Phosphorylation of Syk and PLCg1/2, but (Van Lint et al., 1995). Amino acid sequence analysis of
the putative intracellular substrates revealed that cyto-Not of PKCm
Tyrosine phosphorylation of numerous substrates oc- plasmic tails (CT) of Iga, Igb, CD22, and CD19, as well
as Syk, PLCg1, and SHP1, contain possible motifs forcurs following BCR cross-linking, so we tested whether
PKCm is tyrosine phosphorylated after BCR ligation. PKCm phosphorylation. A panel of glutathione S-trans-
ferase (GST), maltose-bindingprotein (MalBP), and TRX-PKCm was immunoprecipitated alone (Figure 4A) or with
associated proteins (Figure 4B) either before or after Tag fusion proteins containing different regions of sig-
nal-transducing molecules was used as a substrate foranti-IgM cross-linking, and tyrosine-phosphorylated
proteins were detected by Western blotting. PKCm had PKCm. GST, MalBP, TRX-Tag, and the cytoplasmic tail of
CD40 served as negative controls. Table 1 summarizesa low basal level of tyrosine phosphorylation, which did
Syk-Dependent Regulation of PKCm in BCR Signaling
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Figure 4. Tyrosine Phosphorylation of PKCm
and Associated Proteins after BCR Cross-
Linking
Syk, PLCg1, PLCg2, and PKCmwere immuno-
precipitated from B cell line Ramos before
and after BCR ligation and washed with high
salt buffers (A) or with NP-40 (B and C). (A)
and(B) show Western blotting with anti-phos-
photyrosine antibody. In (C), PLCg1 was
detected in PKCm immunoprecipitates by
Western blotting with anti-PLCg1 antisera.
Western blotting was performed using en-
hanced chemiluminescence. One of four ex-
periments is shown.
results of in vitro kinase assays with potential substrates However, mutation of these serines to alanine did not
change the level of phosphorylation of GST–g1SH2based on over seven experiments. Moderate substrates
for PKCm include the linker region of Syk (GST–SykLR) (C)SH3 fusion protein (Table 1). Possibly, the SH3 do-
main of PLCg1 is necessary for optimal binding to PKCmand the region of PLCg1 containing SH2(C) and SH3
domains (GST–g1SH2(C)SH3). The level of phosphoryla- and to allow efficient phosphorylation of the PLCg1
SH2(C) domain. Both wild-type and null mutants of thetion of GST–g1SH2(C)SH3 was consistently 2- to 3-fold
higher than GST–g1SH2(C), possibly indicating that one phosphatase domain of SHP1 were good substrates for
PKCm; however, we were not able to detect associationor both serine residues in the SH3 domain of PLCg1
(Ser-815 and Ser-846) may be specific targets for PKCm. of PKCm and SHP1 in vivo (data not shown). In contrast,
Table 1. Phosphorylation of Substrates by PKCm
Relative Level of Phosphorylationa
2 1 11 111
GST, MalBP GST–SykSH2(NC) GST–SykLRb MBP
TRX-Tag GST–g1SH2(N) GST–g1SH2(C)SH3 Enolase
GST–IgaCTb GST–g1SH2(C) GST–g1SH2(C)SH3S815A MalBP–SHP1PTP
GST–IgaCT(PY) GST–g1SH2(NC) GST–g1SH2(C)SH3S846A MalBP–SHP1PTPC455S
GST–IgbCT GST–BtkSH3
GST–IgbCT(PY) GST–BtkPH
GST–mCD22CT
GST–CD40CT
GST–SykATP2KDb
GST–FynSH2
GST–LynSH2
GST–BtkSH2
MalBP–SHP1SH2
TRX-Tag–g1S1248
a Minus indicates , 1.2 of the level of control phosphorylation; plus, 1.3- to 1.9-fold over control phosphorylation; double plus, 2.0- to 2.9-
fold over control phosphorylation; triple plus, . 3.0-fold over control phosphorylation. A summary of seven experiments is shown.
b CT, cytoplasmic tail; KD, kinase domain; LR, linker region; PY, phosphotyrosine; MalBP, maltose-binding protein.
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Figure 5. PKCm Activity in Chicken B Cell
Line DT40 and DT40 Mutant Cell Lines Defi-
cient in Syk, Lyn, Btk, or PLCg2
PKCm was immunoprecipitated before (mi-
nus) and after (plus) BCR cross-linking and
subjected to in vitro kinase assays with MBP.
A Syk-deficient DT40 subline was transfected
with human wild-type Syk (lanes 5 and 6) and
kinase-dead mutant (lanes 7 and 8). Equal
loading of samples was confirmed by West-
ern blot with anti-PKCm serum. (A) shows
MBP phosphorylation; (B) shows phos-
phorimaging analysis. One of four experi-
ments is shown. BCR-induced activation of
PKCm is Lyn independent and is regulated by
Syk, PLCg2, and Btk. The kinase activity of
Syk is required for PKCm activation.
PKCm did not phosphorylate cytoplasmic tails of CD22, kinase activity, the association of PKCm with Syk and
PLCg1/2 raised two possibilities: either PKCm may actCD19, CD40, Iga, or Igb. Furthermore, prior tyrosine
phosphorylation of IgaCT and IgbCT expressed in the as an intermediate link between Syk and PLCg1/2 or,
alternatively, PKCm may be downstream from PLCg1/2.TKX1 Escherichia coli strain (induced to express the
epidermal growth factor receptor kinase domain) did To answer this question, we used a PLCg2-deficient
subline of DT40. Unlike wild-type cells, cross-linking ofnot enable PKCm to phosphorylate these proteins. The
SH2 domains of Syk and PLCg1, and also the Pleckstrin sIgM on PLCg2-deficient cells did not activate PKCm,
supporting the hypothesis that PKCm is downstreamhomology (PH) and SH3 domains of Btk, were weak
substrates for PKCm, while the SH2 domains of Lyn, from PLCg2 in the signaling cascade. Interestingly, the
magnitude of PKCm activation, like PLCg2 activationFyn, Btk, and SHP1 were not phosphorylated by PKCm.
PKCm also did not phosphorylate the kinase domain of (Takata and Kurosaki, 1996), was greatly reduced in
a Btk-deficient subline (Figure 5), as expected. TakenSyk, nor the putative negative regulatory site of PLCg1,
Ser-1248 (Table 1). Taken together with the structural together, these data suggest that PKCm activation re-
quires activation of PLCg2 since, like PLCg2, it requiresdata above (Figures 1–3), these data suggest that Syk
and PLCg1 are the most likely specific targets for PKCm Syk but not Lyn.
phosphorylation in B cells.
Feedback Regulation of BCR-Induced Tyrosine
Phosphorylation of PLCg1 by PKCmRequirements for PKCm Activation in B Cells
Our results above indicated that PKCm is a component of The association of PKCm with Syk and PLCg1/2, and
the in vitro substrate specificity of PKCm, raised thethe signal transduction pathway initiated by BCR cross-
linking and involving Syk and PLCg1/2. To place PKCm possibility that PKCm may phosphorylate Syk, PLCg1/2,
or both in cells and affect tyrosine phosphorylation ofmore precisely in the BCR signaling cascade, we used
the chicken B cell line DT40 and DT40 mutant cell lines PLCg1/2 by Syk. Tyrosine phosphorylation of Syk and
PLCg1/2 is a positive regulator of theiractivities (Pleimandeficient in Syk, Lyn, Btk, or PLCg2 (Takata et al., 1994,
1995; Takata and Kurosaki, 1996). Mutant sublines of et al., 1994a). Serine phosphorylation of PLCg1 is known
to be a negative regulator of its activity, but it is notDT40 display different degrees of PLCg2 activation and
Ca21 mobilization after BCR cross-linking. For measur- known how Syk activity is turned off. To test the hypoth-
esis that PKCm could modulate the ability of Syk toing chicken PKCm activity, we immunoprecipitated
PKCm before and after BCR cross-linking and measured phosphorylate PLCg1, we immunoprecipitated Syk and
PKCm together from the Ramos B cell line before andphosphorylation of MBP by PKCm in in vitro kinase
assays (Figures 5A and 5B). As in human B cell lines, after sIgM cross-linking and subjected them to in vitro
kinase assays (Figures 6A and 6B). The negative controlPKCm was activated in wild-type DT40 cells after sIgM
cross-linking The same up-regulation of PKCm activity for phosphorylation was normal rabbit IgG instead of
anti-PKCm antiserum. In these experiments, we testedwas also detected in Lyn-deficient cells. In contrast, in
the Syk-deficient line, BCR cross-linking did not induce the ability of Syk to phosphorylate a preferred substrate
in vitro after incubation for 10 min with PKCm. The sub-PKCm activation. Furthermore, transfection of wild-type
human Syk, but not a kinase-dead mutant of Syk, com- strate was GST–g1SH2(C)SH3 fusion protein of PLCg1,
which contained two key regulatory residues, Tyr-771pletely restored PKCm activation by BCR ligation (Figure
5). Mutation of the autophosphorylation site of Syk (Tyr- and Tyr-783, that are targets for Syk phosphorylation
(Law et al., 1996a). Phosphoproteins were resolved by525 and Tyr-526) in the Syk kinase domain also com-
pletely inhibited the BCR-inducible activity of PKCm sodium dodecyl sulfate–polyacrylamide gel electropho-
resis (SDS–PAGE), and phosphorimaging and phos-(data not shown). Hence, the kinase activity of Syk is
required for PKCm activation. phoamino acid analysis were performed. After in vitro
kinase assay of samples in which Syk and PKCm wereSince PLCg1 activation and Ca21 fluxes require Syk
Syk-Dependent Regulation of PKCm in BCR Signaling
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Figure 6. Down-Regulation of the Ability of Syk to Phosphorylate GST–g1SH2(C)SH3 by PKCm
The Ramos cell line was activated by IgM ligation for 3 min, and Syk was immunoprecipitated together with PKCm (A, lanes 3 and 4) and
subjected to in vitro kinase assays with GST–g1SH2(C)SH3. The addition of an appropriate amount of normal rabbit IgG instead of anti-PKCm
antibodies was a control (A, lanes 1 and 2).
(B) shows phosphorimaging analysis of GST–g1SH2(C)SH3 phosphorylation. After incubation of Syk with PKCm, the level of GST–g1SH2(C)SH3
phosphorylation was 42% lower than in control, and the actual decrease of tyrosine phosphorylation was 63%. PKCm was phosphorylating
both Syk and substrate on serine residues (D and F); however, in control samples only tyrosine phosphorylation was detected (C and E). The
positions of standard amino acids, phosphoserine, phosphothreonine, and phosphotyrosine, are shown by broken lines as in Figure 2E. One
of three experiments is shown.
immunoprecipitated together, Syk was phosphorylated (data not shown). The inhibition of the ability of Syk to
phosphorylate GST–g1SH2(C)SH3 in vitro suggests thaton both tyrosine and serine residues (Figure 6D), unlike
Syk from control samples (Figure 6C). In these samples, PKCm may function in the feedback regulation of BCR-
induced activation of PLCg1.where Syk was immunoprecipitated together with
PKCm, the level of phosphorylation of GST–g1SH2(C)
SH3 substrate was 37%–42% lower than that in the Discussion
control samples. Since GST–g1SH2(C)SH3 was a poten-
tial substrate for both Syk and PKCm, we examined the A Ser/Thr Kinase PKCm Associates with the BCR
Ser/Thr kinase activity has been detected in the BCRcontribution of Syk and PKCm to the level of phosphory-
lation by phosphoamino acid analysis of the fusion pro- (Leprince et al., 1992; Van Noesel et al., 1990, 1991,
1992; Williams et al., 1994). Components of the BCR,tein. As was expected, the fusion protein was phosphor-
ylated on both tyrosine and serine when PKCm and Syk including Iga and Igb, and the coreceptor molecule
CD22 can be phosphorylated on serine and threoninewere incubated together (Figures 6E and 6F). Impor-
tantly, the phosphorylation level of GST–g1SH2(C)SH3 residues (Leprince et al., 1992, 1993; Van Noesel et al.,
1990). Syk, which interacts with both the BCR andafter coincubation with Syk and PKCm underrepresents
the decreased activity of Syk in this assay, since the PLCg1/2, also coprecipitates with a Ser/Thrkinase activ-
ity that is up-regulated after anti-IgM activation (Sidor-lower levels of tyrosine phosphorylation by Syk were
masked by phosphorylation on serine by PKCm (Figure enko et al., 1995). In the Jurkat T cell line, PLCg1 was
shown to associate with a Ser/Thr kinase activity (Gilli-6B). The decrease in phosphorylation of GST–g1SH2
(C)SH3 on tyrosine after Syk and PKCm coincubation land et al., 1992). However, the identity of Ser/Thr ki-
nases associated with antigen receptors and their roleswas confirmed by cold in vitro kinase assay followed
by Western blotting with anti-phosphotyrosine antibody in signaling cascades have remained unclear. Here, we
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identified a Ser/Thr kinase associated with BCR as an activated by DAG in vivo, i.e., possibly downstream of
PLCg1/2 activation. PKCm activity is not up-regulatedatypical member of the PKC family, PKCm. Using se-
quential immunoprecipitation after invitro kinase assays after BCR cross-linking of PLCg2-deficient DT40 cells
(Figure 5).This result places PKCm downstream of PLCg,and Western blotting, we also found that PKCm copre-
cipitates with Syk, PLCg1, and PLCg2. Structural and consistent with PKCm regulation in vivo by DAG. In addi-
tion, regulation of PKCm by PLCg1/2 may also involvebiochemical features of human PKCm and its mouse
homolog, protein kinase D, have been described (Johan- direct intermolecular interactions. For example, the mi-
togenic properties of PLCg do not require its catalyticnes et al., 1994, 1995; Valverde et al., 1994; Van Lint et
al., 1995); however, its possible function and links to activity (Huang et al., 1995; Smith et al., 1994), and the
SH3 domain of PLCg is necessary but not sufficient tosignal transduction pathways were unknown.
PKCm was reported to have a constitutive kinase ac- initiate a mitogenic response (Huang et al., 1995). PKCm
activation is Lyn independent, but depends on Syk ki-tivity (Johannes et al., 1994, 1995). In B and T lympho-
cytes, we also found a basal level of PKCm activity and nase activity and is also regulated by Btk, consistent
with parallel findings showing that, as with PKCm, PLCg2autophosphorylation (Figure 2). The activity of PKCm
was elevated by cross-linking either the BCR, TCR, or tyrosine phosphorylation and activation requires Syk,
but not Lyn, and is regulated by Btk (Takata and Kuro-CD19 (Figure 3), all of which activate PLCg1/2 and in-
duce release of intracellular Ca21 (Carter et al., 1991a, saki, 1996; Takata et al., 1994).
1991b; Rijkers et al., 1990; Weiss and Littman, 1994).
This is consistent with the fact that PLCg2 is required for
PKCm Involvement in BCR-Activated SignalPKCm activation in thechicken B cell line DT40 (Figure5).
Transduction Pathways
Since PKCm is associated with BCR, we attempted to
identify possible substrates for PKCm using fusion pro-How Is PKCm Regulated by the BCR?
The association of PKCm with Syk and PLCg1/2 and the teins of cytoplasmic tails of different molecules partici-
pating in signal transduction via BCR. PKCm failed toactivation of PKCm by surface receptors activating PLCg
suggest that PKCm is linked to Syk-mediated activation phosphorylate the cytoplasmic tails of Iga, Igb, CD22,
and also CD40 invitro (Table 1). This indicates that PKCmof PLCg. Syk is a crucial element in tyrosine phosphory-
lation and activation of PLCg1/2 in lymphocytes (Kola- may not be the only Ser/Thr kinase associated with
BCR and that Ser/Thr kinases other than PKCm may benus et al., 1993; Takata et al., 1994). The SH2 domains
of PLCg1 may directly interact with Syk, and Syk is responsible for serine phosphorylation of Iga, Igb, and
CD22 in vivo and in vitro (Leprince et al., 1992; Vanresponsible for in vitro phosphorylation of a key regula-
tory tyrosine residue, Tyr-783, known to be involved in Noesel et al., 1991). PKCm, however, could use both Syk
and PLCg1 as in vitro substrates. The serine phosphory-in vivo activation of PLCg1 (Law et al., 1996a). In Syk-
deficient cell lines, PKCm was not activated after IgM lation of Syk detected after in vitro kinase assays (Sidor-
enko et al., 1995) may be mediated by PKCm. Indeed,cross-linking (Figure 5). Transfection of functionally ac-
tive human Syk into the Syk-negative cells completely using fusion proteins of functional domains of Syk, we
found that PKCm can phosphorylate the linker regionreconstituted PKCm activity, while transfection of inac-
tive Syk did not. Hence, the BCR-induced up-regulation and SH2 domains of Syk, but not its kinase domain
(Table 1).of PKCm activity depends on the kinase activity of Syk,
and, therefore, PKCm appears to be downstream of Syk. A number of studies suggest that PTK activity can be
down-regulated by Ser/Thr phosphorylation. PKC acti-The level of PKCm protein coprecipitated with PLCg1
before and after BCR cross-linking remained unchanged vation is known to down-modulate the signaling poten-
tial of the epidermal growth factor and insulin receptors(Figure 4C). As was expected, the level of tyrosine phos-
phorylation of PLCg1 coprecipitated with PKCm was (Seedorf et al., 1995). The nonreceptor tyrosine kinase
Btk, which binds to different isoformsof PKC in vitro, canelevated by BCR cross-linking (Figure 4B). Despite the
tyrosine phosphorylation of PKCm in vitro by associated also be negatively regulated by PKC-mediated serine
phosphorylation (Yao et al., 1994). PKCm inhibition ofPTK (Figure 2F), we did not detect any BCR-induced
changes in tyrosine phosphorylation of PKCm (Figure the ability of Syk to phosphorylate the Z region of PLCg1
(Figure 6) may be mediated by a similar mechanism and4A). Therefore, PKCm activation may not require its tyro-
sine phosphorylation. presumably reflects negative feedback regulation of Syk
activity by PKCm. Alternatively, since PKCm, like Syk,PKCm lacks a C2 region responsible for Ca21 binding
(Johannes et al., 1994). Addition of Ca21 did not affect may phosphorylate and bind to the Z region of PLCg1,
it may affect the binding capacity and enzymatic actionthe activity of PKCm (Johannes et al., 1994, 1995) or its
mouse homolog PKD (Van Lint et al., 1995). Neither of Syk via steric inhibition. Whether PKCm directly inhib-
its the enzymatic activity of Syk or alters its ability toEGTA, which prevents the influx of extracellular Ca21,
nor ionomycin, which releases Ca21 from intracellular interact with PLCg1/2 (or both) remains to be clarified.
Phosphorylation of PLCg1 at Tyr-783 and Tyr-1254 isstores, affected PKCm activity in B cells. This suggested
that PKCm is a Ca21-independent kinase and therefore known to be a positive regulatory signal for PLCg1-
mediated hydrolysis of inositol phospholipids (Kim etmight not require activation of PLCg1/2. However, the
presence of tandem cysteine-rich zinc finger–like motifs al., 1991). On the other hand, phosphorylation of PLCg1
at Ser-1248 may inhibit PLCg1 function (Berridge, 1993;confers phorbol ester and DAG binding and activation
of PKCm (Dieterich et al., 1996; Johannes et al., 1995; Park et al., 1992). Ser-1248 is only one of several nega-
tive regulatory sites in PLCg1. Both PKA and PKC couldVan Lint et al., 1995). This suggests that PKCm can be
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and different sera to each molecule gave similar results. F(ab9)2phosphorylate PLCg1 and down-regulate its activity;
fragments of goat anti–human IgM (Jackson ImmunoResearch) andhowever, serine targets for this phosphorylation were
mouse anti–chicken IgM MAb M4 (Chen et al., 1982) were used fornot mapped (Park et al., 1992). PKCm was not able to
IgM cross-linking on human and chicken B cell lines, respectively.
phosphorylate a fusion protein containing Ser-1248 in F(ab9)2 fragments of mouse MAb against CD3 (64.1), CD19, CD22,
vitro, but did phosphorylate the Z region of PLCg1, con- and CD40 were prepared using immobilized pepsin (Pierce). F(ab9)2
fragments of goat anti–mouse IgG (Jackson ImmunoResearch) weretaining SH2 and SH3 domains (Table 1). Mutations of
used as secondary cross-linking reagent with F(ab9)2 fragments ofserine residues in the PLCg1 SH3 domain show that the
mouse MAb. Glutathione–agarose was purchased from Sigma, andtargets for PKCm in the Z region of PLCg1 are serines
protein A– and protein G–Sepharose were purchased from Phar-in SH2 domains (Table 1). The requirement of the PLCg1
macia.
SH3 domain for phosphorylation of the SH2 domains
raises the supposition that the SH3 domain of PLCg1 is
Plasmid Constructs
a possible binding site for PKCm. Indeed, the N-terminal A panel of GST, MalBP, and TRX-Tag fusion proteins was used as
region of PKCm has a proline-rich sequence potentially substrate for in vitro kinase assay. The following fusion proteins
capable of interacting with SH3 domains. One testable constructs (with the range of amino acids indicated) were prepared
for this study: GST–IgaCT (182–229), GST–IgbCT (166–226), GST–possibility is that serine phosphorylation of PLCg1 by
mCD22CT (733–868), GST–BtkPH (1–218), GST–BtkSH3 (212–274),PKCm affects the activity or binding capacities (or both)
GST–BtkSH2 (274–386), GST–FynSH2 (145–250), GST–SykLR (260–of PLCg1.
384), GST–SykATP2KD (367–635), GST–LynSH2 (125–231), MalBP–
The PH domain, located between the tandem of SHP1PTP (208–597). Forward and reverse primers with the ap-
cystein-rich zinc finger–like domains and the kinase do- propriate restriction sites for in-frame cloning into the pGEX-2T,
main of PKCm, is another region that could potentially pMAL-c2, and pET-32(a) plasmids were used to amplify the various
cDNA fragments using pfu polymerase (Stratagene). The templatemediate interaction of PKCm with Syk, PLCg1/2, or both.
used for amplifying the cytoplasmic domains of Iga (IgaCT) and IgbPH domains can bind to the bg complexes of heterotri-
(IgbCT), the SH2 domains of Fyn (FynSH2) and Lyn (LynSH2), andmeric G proteins (Touhara et al., 1994; Tsukada et
the SH3 domain of PLC-g1 (g1SH3) was first strand cDNA derivedal., 1994) and phosphatidylinositol (4,5)bisphosphate,
from the Daudi Burkitt’s lymphoma B cell total RNA synthesized
which could serve as an anchor for binding to mem- using Superscript reverse transcriptase (Life Technologies). The
branes (Harlan et al., 1994; Pawson, 1995). Another very template used for amplifying the cytoplasmic domain of mouse
interesting possibility is that PH domains function in CD22 (mCD22CT) was a full-length mCD22 cDNA clone (Law et al.,
1993). The template used for amplifying the BTK PH (BtkPH), SH3the recognition of phosphorylated Ser/Thr residues in
(BtkSH3), and SH2 (BtkSH2) domains was a full-length human Btkspecific peptide sequences (Gibson et al., 1994). The
cDNA clone provided by Dr. C. I. Edvard Smith (Karolinska Institute,most likely site for binding of PH domains of both PKCm
Sweden). The template for amplifying the linker region of Syk (SykLR)
and PLCg1 is the linker region of Syk. This linker region was a full-length human Syk cDNA clone (Law et al., 1994), and the
between SH2 and kinase domains has ten serine resi- template used to amplify a dead kinase domain (SykATP2KD) of Syk
dues, four of which are located in the alternatively was the mCD8-SykATP2 plasmid described recently (Law et al.,
1996b). The templates used for amplifying the wild-type phospha-spliced region of 23 amino acids that is absent in Zap70
tase domain (SHP1PTP) and the dead phosphatase domain(Rowley et al., 1995; Yagi et al., 1994). This alternatively
(SHP1PTP-C455S) of SHP1 have also been described (Law et al.,spliced region also has three serine residues that are
1996b). Nucleotide fidelity for all constructs was confirmed by se-possible substrates for PKCm (Table 1). Alternatively,
quencing. Plasmids with the correct nucleotide sequences were
since the PLCg1 SH2(C) domain binds to Tyr-348 and transformed into the bacterial strain BL21(DE3) for fusion protein
Tyr-352 in the Syk linker region (Law et al., 1996a), asso- production. Plasmids containing GST–IgaCT and GST–IgbCT were
ciation of Syk with PKCm may be indirect and could be also transformed into E. coli strain TKX1 (Stratagene) for production
of tyrosine-phosphorylated GST–IgaCT and GST–IgbCT. Tyrosinemediated by PLCg1. The tissue distributions of PKCm
phosphorylation of these fusion proteins was apparently restrictedand PLCg are ubiquitous. Hence, it is possible that Syk-
only to the corresponding cytoplasmic tails, as GST was not tyrosinedependent activation of PKCm via PLCg with feedback
phosphorylated when expressed alone in the same bacterial strain
regulation is a particular case of a general mechanism (data not shown). Procedures for generating GST–SykSH2(NC),
of negative regulation of signal transduction initiated by GST–g1SH2(N), GST–g1SH2(C), GST–g1SH2(NC), GST–g1SH2(C)
PTK, including growth factor receptors. SH3 (same as GST–g1Y771,783), and MalBP–SHP1SH2 (same as
MBP–1CSH2(NC)) have recently been described (Law et al., 1996a,
1996b). GST–g1SH2(C)SH3 was mutagenizedby site-directed muta-Experimental Procedures
genesis using the U.S.E. kit (Pharmacia) to generate GST–g1
SH2(C)SH3S815A and GST–g1SH2(C)SH3S846A. Expression andCells, Antibodies, and Reagents
purification of GST and MalBP fusion proteins were performed asThe Burkitt’s lymphoma cell lines Daudi and Ramos, the lymphoma
described (Law et al., 1996b).cell line B104, the pre-B cell lines Reh and Nalm6, the lymphoblas-
toid cell line CESS, the Jurkat T cell line, and COS cells were main-
tained as described previously (Law et al., 1994). Generation of Transfection of DT40 Chicken Cell Line
Lyn-, Syk-, PLCg2-, and Btk-deficient chicken cell lines and the The coding region of human Syk was cloned into KpnI–SalI-cut
conditions for cultivation of DT40 wild type and mutants were as pApuro2. This plasmid was linearized and electroporated into the
previously described (Takata et al., 1994, 1995; Takata and Kurosaki,
Syk-deficient DT40 cells (Takata et al., 1994) at 250 V and 960 mF.
1996). Hybridomas secreting monoclonal antibodies (MAbs) against
Stable transfectants were selected using 1 mg/ml of puromycin.
CD19 (HD37) and CD22 (HD39) were provided by Dr. Anthony Pez- Expression of human Syk in puromycin-resistant cells was con-
zutto (Universitat Heidelberg, Germany); rabbit anti-PLCg1 and anti- firmed by SDS–PAGE and Western blotting.
PLCg2 sera were the gift of Dr. Graham Carpenter (Vanderbilt Univer-
sity). Rabbit antisera against Syk, PLCg1, PLCg2, PKCm, and p120cbl
Cell Stimulationwere purchased from Santa Cruz Biotechnology. Mouse MAbs
B and T cells were stimulated by ligating cell surface antigens withagainst PLCg1 and biotinylated anti-phosphotyrosine MAb 4G10
antibodies as described (Law et al., 1996a, 1996b). Cross-linking of(Upstate Biotechnology) were used for Western blotting. Rabbit anti-
sera against PLCg1 and PLCg2 were used for immunoprecipitations, CD19, CD22, CD40, and CD3 was performed in two steps, using
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F(ab9)2 fragments of antigen-specific MAbs, followed by F(ab9)2 frag- immunoglobulin in B lymphocytes. Proc. Natl. Acad. Sci. USA 88,
2745–2749.ments of goat anti–mouse IgG. Phorbol myristate acetate (PMA)
was used at a concentration of 50 ng/ml and ionomycin at a concen- Carter, R.H., Tuveson, D.A., Park, D.J., Rhee, S.G., and Fearon,
tration of 500 ng/ml. D.T. (1991b). The CD19 complex of B lymphocytes: activation of
phospholipase C by a protein tyrosine kinase-dependent pathway
Biochemical Methods that can be enhanced by the membrane IgM complex. J. Immunol.
Cell lysis, immunoprecipitation, SDS–PAGE, in vitro kinase assay, 147, 3663–3671.
and phosphoamino acid analysis were performed as previously de- Chen, C.L., Lehmeyer, J.E., and Cooper, M.D. (1982). Evidence for
scribed (Law et al., 1994; Leprince et al., 1992). Western blotting was an IgD homologue on chicken lymphocytes. J. Immunol. 129, 2580–
performed with an enhanced chemiluminescence kit (Amersham Life 2585.
Science). For evaluation of PKCm activity alone, immunoprecipitates
DeFranco, A.L. (1995). Transmembrane signaling by antigen recep-of PKCm were washed twice with NP-40 lysis buffer containing 0.5
tors of B and T lymphocytes. Curr. Opin. Cell Biol. 7, 163–175.M NaCl, twice with high salt buffer (0.5 M LiCl), and once with NP-
Dieterich, S., Herget, T., Link, G., Bottinger, H., Pfizenmaier, K.,40 lysis buffer and were subjected to in vitro kinase assays with
and Johannes, F.-J. (1996). In vitro activation and substrates ofMBP or fusion proteins as potential substrates. The concentration
recombinant, baculovirus expressed human protein kinase Cm.of substrates was 50 mg/ml. Immunoprecipitates were incubated
FEBS Lett. 381, 183–187.for 15 min at 308C in 20 ml of kinase buffer (40 mM PIPES, 10 mM
MgCl2, 10 mM MnCl2 [pH 7.0]) with 10 mCi of [g-32P]ATP (300 Ci/mM; Fukazawa, T., Reedquist, K.A., Trub, T., Soltoff, S., Panchamoorthy,
DuPont New England Nuclear). The reaction was stopped by boiling G., Druker, B., Cantley, L., Shoelson, S.E., and Band, H. (1995). The
for 5 min with 20 ml of 23 sample buffer containing 30 mM EDTA. SH3 domain-binding T cell tyrosyl phosphoprotein p120: demon-
Phosphorimaging analysis was performed using PhosphorImager stration of its identity with the c-cbl protooncogene product and in
SF and ImageQuant software (Molecular Dynamics). For experi- vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase.
ments measuring the ability of Syk to phosphorylate a preferred J. Biol. Chem. 270, 19141–19150.
substrate after PKCm phosphorylation, Syk and PKCm were immu-
Gibson, T.J., Hyvonen, M., Musacchio, A., Saraste, M., and Birney,
noprecipitated together and subjected to in vitro kinase assays.
E. (1994). PH domain: the first anniversary. Trends. Biochem. Sci.
After 10 min of incubation with 10 ml of kinase buffer (see above)
19, 349–353.
with 5 mCi of [g-32P]ATP, GST–g1SH2(C)SH3, the substrate for mea-
Gilliland, L.K., Schieven, G.L., Norris, N.A., Kanner, S.B., Aruffo, A.,suring of Syk activity, was added in an additional 10 ml of kinase
and Ledbetter, J.A. (1992). Lymphocyte lineage-restricted tyrosine-buffer with 5 mCi of [g-32P]ATP, and immunoprecipitates were incu-
phosphorylated proteins that bind PLCg1 SH2 domains. J. Biol.bated another 10 min. All samples, including controls, were incu-
Chem. 267, 13610–13616.bated the same way for the same periods of time. Proteins were
resolved by SDS–PAGE and phosphorimaging, and phosphoamino Gold, M.R., Sanghera, J.S., Stewart, J., and Pelech, S.L. (1992).
acid analysis were performed. Selective activation of p42 mitogen-activated protein (MAP) kinase
Sequential immunoprecipitation was performed as described pre- in murine B lymphoma cell lines by membrane immunoglobulin
viously with some modifications (Sidorenko et al., 1995). In brief, cross-linking: evidence for protein kinase C-independent and
after primary immunoprecipitations with rabbit or mouse antibodies -dependent mechanisms of activation. Biochem J. 287, 269–276.
and in vitro kinase assays, 32P-labeled bands of interest were ex- Harlan, J.E., Hajduk, P.J., Yoon, H.S., and Fesik, S.W. (1994). Plecks-
cised from dried gels, and proteins were eluted in 50 mM Tris buffer trin homology domains bind to phosphatidylinositol-4,5-bisphos-
(pH 8.0) containing 0.1 mM EDTA, 150 mM NaCl, and 0.1% SDS. phate. Nature 371, 168–170.
Prior to secondary immunoprecipitations, inhibitors of proteases
Huang, P.S., Davis, L., Huber, H., Goodhart, P.J., Wegrzyn, R.E.,and phosphatases were added. To reduce nonspecific binding, NP-
Oliff, A., and Heimbrook, D.C. (1995). An SH3 domain is required for40 and bovine serum protein were added to final concentrations of
the mitogenic activity of microinjected phospholipase C-g1. FEBS0.5% and 0.1%, respectively. After secondary immunoprecipita-
Lett. 358, 287–292.tions, proteins were resolved by SDS–PAGE.
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